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1607-551X/Copyright ª 2015, KaohsiuAbstract Interleukin (IL)-1b is a potent inhibitor of gastric acid secretion and its genetic poly-
morphism is linked to the severity of reflux esophagitis. Proton-pump inhibitor (PPI) metabolized
by P450 2C19 (CYP2C19) is the chiefmedication in reflux esophagitis treatment. The CYP2C19 ge-
notypemay influence the therapeutic effect of PPI for reflux esophagitis. FromNovember 2009 to
June 2012, 184 patients were enrolled in this study with endoscopy examination, 8 weeks of
esomeprazole treatment, and 20 weeks of follow-up with questionnaire. These patients also
received endoscopy examination after 20 weeks. Blood was collected for genetic polymorphism
analysis with polymerase chain reaction. After 8 weeks of treatment with esomeprazole, all of
these 184 patients had achieved complete symptom relief. However, in the following 12 weeks,
58.70% (108/184) complained of symptom relapse, 45.65% (84/184) patients had persistent
esophageal erosion verified by endoscopy, and in total, 76.09% (140/184) patients had treatment
failure at the end of 20 weeks. There were no influences between the genetic polymorphisms of
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no relationships between IL-1b and CYP2C19 in the treatment effect in mild reflux esophagitis.
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Gastroesophageal reflux disease (GERD), defined as the
reflux of stomach contents, causes troublesome symptoms
and complications, and is a common chronic disorder
prevalent in many countries [1,2]. In Asia, the prevalence
of gastroesophageal reflux disease was previously believed
to be < 5% but has increased to 15% in recent studies and is
considered an important health issue in the future [3e5]. In
previous studies, reflux esophagitis was regarded as a
multifactorial disease influenced by environmental factors
such as dietary behavior, substance usage, and a host of
physiological factors [4]. In the past decade, gene studies
have bloomed and interleukin (IL)-1b has been shown to be
associated with acid-related diseases such as peptic ulcer
and reflux esophagitis [6e8]. Proton-pump inhibitor (PPI)
has been the mainstay of medical treatment in acid-related
diseases including peptic ulcer and gastroesophageal reflux
disease [9]. After widespread and understated use of this
medication, the metabolism pathway was considered to
have influence on therapeutic effect. Cytochrome 450 en-
zymes in the liver provide the major pathway for PPI
metabolism and the genotype of CYP2C19 has shown
distinct influence in pharmacodynamics of PPI. The genetic
polymorphism of CYP2C19 has been proven to have influ-
ence on PPI-based Helicobacter pylori eradication [10,11].
Some reports have also shown it to have influence in the
treatment of gastroesophageal reflux disease [12,13].
Our aim was to determine the influence of genetic
polymorphisms of IL1B and CYP2C19 on the treatment of PPI
in reflux esophagitis.Materials and methods
Patients
From November 2009 to June 2012, we studied 184 patients
subjected to endoscopic units for esophagogas-
troduodenoscopy examination in the city of Kaohsiung,
Taiwan, including Kaohsiung Medical University Hospital,
Kaohsiung Veterans General Hospital, and Kaohsiung Chang
Gung Memorial Hospital. All patients suffered from symp-
toms of reflux esophagitis such as heartburn, acid regurgi-
tation, dyspepsia, noncardiac chest discomfort, globus
sensation, and cough or epigastric soreness. Patients who
had ever been treated with acid-suppressive agents (PPI,
H2-blocker) or antacid 2 months prior to endoscopy exam-
ination were excluded. We also excluded patients who had
undergone nonsteroidal anti-inflammatory drug treatment
or who had severe systemic diseases such as chronicpulmonary lung disease, malignant hypertension, and
neurological disease with feeding tube.
Questionnaire
Prior to the endoscopic examination, interviews were taken
with a questionnaire designed for reflux esophagitis that
has been used in a nationwide survey for erosive esophagitis
and nonerosive reflux esophagitis in health check-up eval-
uation [14,15]. The questionnaire evaluated seven reflux
symptoms including acid regurgitation, heartburn sensa-
tion, atypical chest pain, throat globus sensation, cough,
dyspepsia, and epigastric soreness. Besides, medical history
was recorded whether antacid and acid suppressive agent
(H2-blocker or PPI) was taken. Personal history with dietary
habits related to reflux esophagitis was traced i.e., (1)
alcohol consumption (> 80g ethanol/d); (2) smoking (> 1
pack/d); (3) tea or coffee consumption (> 1 cup/d); and (4)
spicy food (> 4 times/wk). The body mass index (BMI) and
biochemical test results and H. pylori (CLO test; Delta
West, Bentley, WA, Australia) or histology results were
entered by research assistants.
Endoscopy
All study participants underwent esophagogastroduodeno-
scopy examination performed by a gastroenterologist with
endoscopy experience.
The severity of erosive esophagitis was classified ac-
cording to Los Angeles Classification AeD based on the
length of mucosa break and confluence of esophageal
erosion over gastroesophageal junction. The presence of
hiatal hernia and endoscopic grading of the gastroesopha-
geal flap valve (GEFV) was assessed [16,17]. H. pylori
presence was checked with rapid urease test (CLO test).
Treatment and follow-up
The patients with GERD symptoms were treated continu-
ously with esomeprazole 40 mg/d for 8 weeks and this was
discontinued after symptom relief. Then, the prescription
of esomeprazole was shifted to an on-demand method: on
experiencing GERD symptoms, esomeprazole 40 mg/d was
administered until symptom relief occurred. Relapse was
defined as recurrent symptoms after complete resolution of
the GERD symptoms. The patients received outpatient
department follow-up every 4 weeks with questionnaire.
Patients received endoscopy examination within the 20
weeks or when severe reflux symptoms attacked. The main
outcome measures were: (1) rate of symptom relapse in the
following 20 weeks; (2) rate of sustained healing of erosive
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treatment. Treatment success was defined as all of these
situations being achieved: stopped treatment of anti-
secretion medication (including PPI and H2-blocker);
endoscopy examination showed no esophageal erosion; and
the patient was free of symptoms. By contrast, any one of
these situations regressing was regarded as treatment
failure. Independent of the genetic polymorphisms of
CYP2C19 and IL1B, all these patients received the same
dose of esomeprazole and strategy of follow-up.
Genetic polymorphisms
IL-1b plays a crucial role in initiating and amplifying the
inflammatory response. It is also a potent inhibitor of
gastric acid secretion. The genetic polymorphism of
IL1Be511 T has shown an association with increased IL-1b
production.
Blood samples were collected into tubes containing
5.4 mg EDTA and used to extract genomic DNA, New En-
gland Biolabs, USA. IL1Be511 T polymorphisms and
CYP2C19 polymorphism were genotyped with the polymer-
ase chain reaction-restriction fragment length poly-
morphism method. Polymerase chain reaction primers and
restriction enzyme sizes of CYP2C19 and IL1Be511 are
shown in Table 1. Products of restriction digest reaction
were separated by 2.5% agarose gel electrophoresis,
stained with ethidium bromide, and visualized under UV
light.
Statistical analysis
Qualitative parameters were analyzed with the Chi-square
test and Fisher’s exact two-sided tests. Analysis of variance
was performed to compare the variation among different
IL-1b polymorphisms. Factors associated with treatment
results were assessed by multiple logistic regression anal-
ysis. We used two-sided p values, with p < 0.05 considered
to be statistically significant. Data were analyzed using
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 184 patients were included in this study. Seventy-
three patients were women and 111 patients men. The
mean age was 52.43  12.56 years, and the BMI
24.94  3.5 kg/m2. The prevalence of alcohol consumption
was 25%, smoking was 18.5%, and tea/coffee consumption
was 43.5%. Upper endoscopy examination showed theTable 1 Polymerase chain reaction primers and restriction enz
Primer Primer sequence
CYP2C19*2 (m1)-F 50-AATTACAACCAGAGCTTG
CYP2C19*2 (m1)-R 50-TATCACTTTCCATAAAAG
CYP2C19*3 (m2)-F 50-ATTGAATGAAAACATCAG
CYP2C19*3 (m2)-R 50-ACTTCAGGGCTTGGTCA
IL1B-511-F 50-TGGCATTGATCTGGTTC
IL1B-511-R 50-GTTTAGGAATCTTCCCAprevalence of H. pylori infection was 24.5%. Among these
184 patients, 47 were LA Grade A reflux esophagitis and the
other 137 patients were Grade B reflux esophagitis. Forty-
three (23.37%) patients had hiatal hernia and 38 cases
(20.65%) had loose GEFV (Grades C or D). According to IL1B
genotype, these 184 patients were divided into three sub-
groups: 33 patients were IL1B genotype T/T, 96 patients
were C/T, and 55 patients were C/C. The analysis of the
univariate demographics is summarized among the ILIB
genotype subgroup (Table 2). There were no differences of
demography between these subgroups except for BMI being
mildly lower in the TT group.
After 8 weeks of treatment with esomeprazole, all 184
patients had achieved symptom relief evaluated by ques-
tionnaire and medication shift to “on demand” according to
patient symptoms. In the following 12 weeks, 58.70% (108/
184) of patients suffered symptom relapse. After logistic
regression analysis, there were no differences between the
subgroup of polymorphisms of CYP2C19 and IL-1b
(p Z 0.745). At 20 weeks, all of these patients received
upper endoscopy examination, which showed that 45.65%
(84/184) had persistent esophageal erosion. Similarly, lo-
gistic regression analysis did not show any differences be-
tween subgroups of polymorphisms of CYP2C19 and IL-1b
(p Z 0.097). At the end of the study, 76.09% (140/184) of
patients were considered as treatment failure due to one of
the situations below being encountered: reloaded anti-
secretion medication (PPI or H2-blocker), endoscopy vali-
dating persistent esophageal erosion, or persistent reflux
symptoms according to patient description. Logistic
regression analysis of polymorphisms of CYP2C19 and IL-1b
also showed no differences (p Z 0.896; Table 3).Discussion
Expression of cytokines such as IL-1b plays an important
role in the infection sites to modulate inflammation and
immune responses and subsequent clinical outcomes. IL-1b
has been extensively discussed in past decades for its role
in chronic gastrointestinal disease. IL-1b has been shown to
become upregulated in gastric mucosa infected with H.
pylori and plays a crucial role in initiating and amplifying
the inflammatory response to H. pylori infection [18]. An
association has also been found between IL1B-511 and -31
polymorphisms and an increased risk of developing gastric
cancer [7]. Recently, acid-related diseases such as reflux
esophagitis have also been investigated [19,20].
The IL1B-511 T allele has been validated with IL-1b
overproduction and lower risk of erosive esophagitis [21].yme sizes of CYP2C19 and IL1Be511.
Restriction enzyme used
GC-30 SmaI 25C overnight (18 h)
CAAG-30
GATTG-30 BamH I 37C overnight (18 h)
ATA-30
ATC-30 Ava I 37C overnight (18 h)
CTT-30
Table 2 Characteristics of the participants (n Z 184).
IL1Be511 genotype p
T/T (n Z 33) T/C (n Z 96) CC (n Z 55) TT vs. TC TC vs. CC TT vs. CC
Sex (M/F) 17/16 59/37 35/20 0.317 0.790 0.263
Age (y) 51.7  11.7 53.9  12.9 50.2  12.9 0.349 0.085 0.580
Alcohol 5 25 16 0.201 0.685 0.137
Smoking 3 18 13 0.195 0.474 0.087
Spicy food 15 36 28 0.420 0.109 0.620
Tea/coffee 17 36 27 0.158 0.165 0.826
BMI 23.7  3.1 25.2  3.6 25.2  3.4 0.027 0.988 0.042
Helicobacter pylori 8 22 15 0.876 0.549 0.754
Hiatal hernia 5 23 15 0.290 0.652 0.189
GEFV (severe/mild) 7/26 20/76 11/44 0.963 0.903 0.891
LA A/B 7/26 24/72 16/39 0.660 0.584 0.415
CYP2C19 (Homo/Heto/PM) 10/20/3 38/45/13 12/33/10 0.391 0.082 0.417
BMI Z body mass index; GEFV Z gastroesophageal flap valve; LA Z Los Angeles classification of erosive gastritis.
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polymorphisms produce higher levels of IL-1b, which
mediate the blockage of gastric acid secretion and protect
against acid reflux and erosive esophagitis [19,20,22].
Because the associations between polymorphism and
gastroesophageal reflux disease are inconsistent, its influ-
ence in GERD treatment is still unknown. So far, PPI has
been the mainstay for medical treatment of peptic ulcer
disease, reflux esophagitis, and H. pylori eradication
[23,24]. Because most available PPIs are metabolized by
cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver,
the genotype polymorphism would affect the activity of this
enzyme and pharmacokinetics/pharmacodynamics of PPI.
In reflux esophagitis, the CYP2C19 polymorphism has been
shown to have influence in maintenance lansoprazole
therapy in erosive esophagitis by Kawamura et al [12].
However, the result of Ohkusa et al [25] showed that long-
term treatment with omeprazole was not influenced by the
cytochrome P450 2C19 metabolic genotype. Similarly, in
the short-term, PPI testing did not influence CYP2C19
polymorphism in Lee et al’s [13] study. Results from Sheu
et al [26] showed the CYP2C19 genotype did not influence
the healing rate in reflux esophagitis Grades C and D.
In this study, we validated all concepts of esomeprazole
in reflux esophagitis including patient subjective symp-
toms, endoscopy findings, and dependence of medication
for symptom relief in patient daily life. All 184 patientsTable 3 Results of esomeprazole treatment in mild reflux
esophagitis.
Polymorphism of IL1B Polymorphism of CYP2C19 p*
Hom Het PM
Symptom relapse (n Z 108)
TT/TC/CC 6/23/10 10/23/18 1/10/7 0.745
Persistent esophageal erosion (n Z 84)
TT/TC/CC 4/16/6 11/27/11 2/3/4 0.097
Treatment failure (n Z 140)
TT/TC/CC 8/26/12 15/34/23 3/11/8 0.896
* Logistic regression analysis.achieved complete symptom relief after 8 weeks of treat-
ment. However, 104 patients complained of symptom
relapse, 84 patients had persistent esophageal erosion
validated by endoscopy, and a total of 140 patients were
treatment failures at the end of the 20-week evaluation.
Although previous studies showed mild esophageal erosion
was healed after 8 weeks of PPI treatment [27], higher
prevalence of symptom recurrence and treatment failures
occurred in our study. This may be related to high preva-
lence of hiatal hernia (23.37%) and loose GEFV (20.65 %
were Grades C or D). Besides, the patient’s subjective
symptoms relapse were also included in the treatment
failure. Due to the above reasons, higher recurrence rate
was found in this study and prolonging PPI treatment and
further lifestyle medication may be warranted for symp-
tomatic mild esophagitis. There was no relationship be-
tween the IL-1b and CYP2C19 in the treatment of mild
esophagitis, and an individual test of genotype offered lit-
tle clinical information in mild reflux esophagitis.
In summary, reflux esophagitis is a disease of wide
spectrum and is associated with multiple possible factors,
including environmental, host, and dietary factors that in-
fluence hyperacidity and esophageal motor dysfunction. In
mild reflux esophagitis, gene polymorphism may not exhibit
influence in the PPI treatment.Acknowledgments
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